



NDA 019651-S027
NDA 204412-S008
NDA 021830-S011

SUPPLEMENT APPROVAL

Allergan Pharmaceuticals International Limited
Attention: Sanket Trivedi
Manager, Regulatory Affairs
Harborside Financial Center
Plaza V, Suite 1900
Jersey City, NJ 07311

Dear Mr. Trivedi:

Please refer to your Supplemental New Drug Application (sNDA) dated and received July 6, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Asacol (mesalamine) Delayed-Release Tablets, 400 mg, Delzicol (mesalamine) Delayed-Release Tablets, 400 mg and Asacol HD (mesalamine) Delayed-Release Tablets 800 mg.

We also refer to our letter dated June 6, 2017, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Mesalamine. This information pertains to the postmarketing experiences of nephrogenic diabetes insipidus and intracranial hypertension.

This supplemental new drug application provides for revisions to the labeling for Mesalamine, consistent with our June 6, 2017 Safety Labeling Change Notification Letter.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your July 6, 2017, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kelly Richards, Regulatory Project Manager, at (240) 402-4276.

Sincerely,

{See appended electronic signature page}

NDA 019651-S027
NDA 204412-S008
NDA 021830-S011
Page 3

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
07/27/2017